Table 2

Additional Drug Resistance of Multidrug-Resistant Tuberculosis in Patients in 9 Countries

Ekaterina V. Kurbatova

, Tracy Dalton, Julia Ershova, Thelma E. Tupasi, Janice Campos Caoili, Martie L. van der Walt, Charlotte L. Kvasnovsky, Martin Yagui, Jaime Bayona, Carmen Contreras, Vaira Leimane, Laura E. Via, HeeJin Kim, Somsak Akksilp, Boris Y. Kazennyy, Grigory V. Volchenkov, Ruwen Jou, Kai Kliiman, Olga V. Demikhova, and J. Peter Cegielski

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (E.V. Kurbatova, T. Dalton, J. Ershova, J. Campos Caoili, C. Kvasnovsky, J.P. Cegielski); Tropical Disease Foundation, Manila, the Philippines (T. Tupasi, J. Campos Caoili); Medical Research Council, Pretoria, South Africa (M. Van Der Walt, C. Kvasnovsky); National Institute of Health, Lima, Peru (M. Yagui); Socios en Salud Sucursal Perú, Lima (J. Bayona, C. Contreras); Riga East University Hospital Centre of Tuberculosis and Lung Diseases, Riga, Latvia (V. Leimane); National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA (L.E. Via); University of Cape Town, Cape Town, South Africa (L.E. Via):; Korean Institute of TB, Seoul, South Korea (H. Kim); Ministry of Public Health, Bangkok, Thailand (S. Akksilp); Orel Oblast Tuberculosis Dispensary, Orel, Russia (B.Y. Kazennyy); Vladimir Oblast Tuberculosis Dispensary, Vladimir, Russia (G.V. Volchenkov); Taiwan Centers for Disease Control, Taipei, Taiwan (R. Jou); Tartu University Hospital, Tartu, Estonia (K. Kliiman); Russian Academy of Medical Sciences, Moscow, Russia (O.V. Demikhova)

Main Article

Individual drug resistance in relation to the profile of fluoroquinolone and SLI resistance among patients with multidrug-resistant tuberculosis who could have been candidates for a short (9-month) treatment regimen or a bedaquiline-containing regimen*

Drug, DST result	Total, N = 1,254	Candidate patients, no. (%)
		Short regimen, FQ-S and SLI-S, n = 952	BDQ-containing regimen
		Short regimen, FQ-S and SLI-S, n = 952	FQ-R or SLI-R,†  n = 302	FQ-R only,  n = 73	SLI-R only,  n = 155	XDR,  n = 74
INH, high-dose
NA	11 (0.9)	11 (1.2)	0	0	0	0
R	1,152 (91.9)	859 (90.2)	293 (97.0)	69 (94.5)	154 (99.4)	70 (94.6)
S	91 (7.3)	82 (8.6)	9 (3.0)	4 (5.5)	1 (0.6)	4 (5.4)
EMB
R	771 (61.5)	553 (58.1)	218 (72.2)	51 (69.9)	113 (72.9)	54 (73)
S	483 (38.5)	399 (41.9)	84 (27.8)	22 (30.1)	42 (27.1)	20 (27)
FQ
R	147 (11.7)	0	147 (48.7)	73 (100)	0	74 (100)
S	1,107 (88.3)	952 (100)	155 (51.3)	0	155 (100)	0
KAN/AMK
R	219 (17.5)	0	219 (72.5)	0	150 (96.8)	69 (93.2)
S	1,035 (82.5)	952 (100)	83 (27.5)	73 (100)	5 (3.2)	5 (6.8)
CAP
NA	9 (0.7)	9 (0.9)	0	0	0	0
R	140 (11.2)	0	140 (46.4)	73 (100)	88 (56.8)	140 (46.4)
S	1,105 (88.1)	943 (99.1)	162 (53.6)	0	67 (43.2)	162 (53.6)
THA
R	232 (18.5)	172 (18.1)	60 (19.9)	8 (11.0)	30 (19.4)	22 (29.7)
S	1,022 (81.5)	780 (81.9)	242 (80.1)	65 (89.0)	125 (80.6)	52 (70.3)
PAS
R	120 (9.6)	48 (5.0)	72 (23.8)	13 (17.8)	28 (18.1)	31 (41.9)
S	1,134 (90.4)	904 (95.0)	230 (76.2)	60 (82.2)	127 (81.9)	43 (58.1)

*AMK, amikacin; BDQ, bedaquiline; CAP, capreomycin; DST, drug-susceptibility testing; EMB, ethambutol; FQ, fluoroquinolone; INH, isoniazid; KAN, kanamycin; NA, not available; PAS, para-aminosalicylic acid; R, resistant; S, susceptible; SLI, second-line injectable drug; THA, ethionamide; XDR, extensively drug-resistant.
†Comprises FQ-R only, SLI-R only, and XDR cases combined.

Main Article

Page created: May 15, 2015

Page updated: May 15, 2015

Page reviewed: May 15, 2015

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.